Having trouble accessing articles? Reset your cache.

CDX-011: Phase II data

In 26 evaluable patients from the Phase II portion of a Phase I/II trial, 1.88 mg/kg IV CDX-011 met the primary endpoint, which required >=5 of 25 (20%) patients in

Read the full 309 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE